Live Analyst Rating Changes 28648 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Alexis Yan
MS

Alexis Yan

Morgan Stanley
Wall Street Analyst
★★☆☆☆
#2277
on 13Foresight · ranked by our own returns
50%
Success Rate
+2.1%
Average Return
7 of 14 calls profitable · -8.3% vs benchmark
S&P 500 (SPY)
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 50% of Alexis Yan's ratings turned a profit when each position was held for 1 year — averaging +2.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

17 Buy 4 Hold 3 Sell
Alexis's Stock Coverage 11 ratings · 2026-08-30
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
HK:9860
ADICON Holdings Limited
 Aug 25, 2026 BUY Strong Buy
+86.1% avg upside
1 analyst
$7.20
86.10% Upside
 · ·
HK:1093
CSPC Pharmaceutical Group
 Aug 20, 2026 BUY Strong Buy
+17.4% avg upside
7 analysts
$11.00
15.44% Upside
 +3.7% ·
HK:1177
Sino Biopharmaceutical
 Aug 19, 2026 BUY Strong Buy
+42.2% avg upside
7 analysts
$7.80
39.39% Upside
 +3.8% ·
HK:1276
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
 Jul 21, 2026 BUY Strong Buy
+135.7% avg upside
2 analysts
$92.00
91.83% Upside
 -16.6% ·
HK:0241
Alibaba Health Information Technology
 May 15, 2026 SELL Buy
+63.1% avg upside
6 analysts
$4.20
33.54% Upside
 +18.2% ·
HK:1530
3SBio
 Jan 13, 2026 BUY Strong Buy
+73.9% avg upside
5 analysts
$38.00
124.11% Upside
 -37.0% ·
HK:6699
Angelalign Technology Inc.
 Jan 07, 2026 HOLD Buy
-5.8% avg upside
2 analysts
$75.00
15.34% Downside
 +39.5% ·
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
 Oct 09, 2025 BUY Strong Buy
+28.2% avg upside
1 analyst
$28.00
28.16% Upside
 -10.1% ·
HK:0853
MicroPort Scientific
 Sep 30, 2025 HOLD Hold
+156.3% avg upside
2 analysts
$16.00
156.33% Upside
 -54.5% ·
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
 Aug 17, 2025 BUY Strong Buy
+70.1% avg upside
2 analysts
$19.00
79.51% Upside
 -37.5% ·
HK:9996
Peijia Medical Ltd.
 Aug 26, 2024 BUY Strong Buy
-25.5% avg upside
1 analyst
$4.00
25.46% Downside
 +163.2% ·
🔒 6 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Alexis Yan — Frequently Asked Questions
How accurate are Alexis Yan's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Alexis's ratings were profitable over a one-year hold, with an average return of +2.1% per rating, or -8.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Alexis ranked on 13Foresight?
Alexis Yan is currently ranked #2277 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Alexis cover?
Alexis most recently has ratings on HK:9860, HK:1093, HK:1177, HK:1276, HK:0241, HK:1530, HK:6699, HK:2190, HK:0853, HK:6078, HK:9996. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.